PRESS RELEASE published on 01/29/2024 at 22:15, 2 years 5 months ago Gedeon Richter becomes strategic investor of Formycon via equity investment Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress Pharmaceutical Industry Formycon AG Gedeon Richter Equity Investment Biosimilars
PRESS RELEASE published on 01/29/2024 at 22:10, 2 years 5 months ago EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor Formycon AG resolves on EUR 82.84 million cash capital increase by issuing 1,603,877 new shares, all subscribed by Gedeon Richter as strategic investor. Proceeds for biosimilar pipeline development. New shares to be traded on Frankfurt Stock Exchange Frankfurt Stock Exchange Formycon AG Cash Capital Increase Gedeon Richter Biosimilar Pipeline
PRESS RELEASE published on 11/10/2023 at 06:30, 2 years 8 months ago Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
PRESS RELEASE published on 10/10/2023 at 07:30, 2 years 9 months ago Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
PRESS RELEASE published on 09/29/2023 at 07:30, 2 years 9 months ago Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
PRESS RELEASE published on 08/30/2023 at 07:30, 2 years 10 months ago Formycon reports successful first half of 2023
PRESS RELEASE published on 08/29/2023 at 07:30, 2 years 10 months ago Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
PRESS RELEASE published on 08/23/2023 at 07:30, 2 years 11 months ago Formycon hosts conference call on financial and earnings position for H1 2023
PRESS RELEASE published on 08/21/2023 at 13:42, 2 years 11 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 08/07/2023 at 08:00, 2 years 11 months ago Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
Published on 07/25/2026 at 00:35, 1 day 13 hours ago Pathfinder Ventures Inc. Provides Corporate Update
Published on 07/24/2026 at 23:00, 1 day 14 hours ago NV Gold Announces Closing of Non-Brokered Private Placement
Published on 07/24/2026 at 22:15, 1 day 15 hours ago Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Published on 07/24/2026 at 22:05, 1 day 15 hours ago Findev Inc. Announces CCAA Proceedings Involving 1682 Victoria Park Avenue Inc. and Related Party Subordination Arrangement
Published on 07/24/2026 at 20:00, 1 day 17 hours ago Unusual Machines to Announce Second Quarter 2026 Financial Results and Provide Corporate Update
Published on 07/24/2026 at 18:44, 1 day 19 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/24/2026 at 17:50, 1 day 20 hours ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 07/24/2026 at 17:40, 1 day 20 hours ago 2CRSi SA: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital as of May 31, 2026.
Published on 07/24/2026 at 18:50, 1 day 19 hours ago Disclosure of transactions in own shares from July 20 to July 24, 2026
Published on 07/24/2026 at 08:00, 2 days 5 hours ago Accor signs a definitive binding agreement on the sale of its stake in Essendi